Clinical assessment of therapeutic effects on cancer using 18F-2-fluoro-2-deoxy-d-glucose and positron emission tomography: Preliminary study of lung cancer

Yoshinao Abe; Taiju Matsuzawa; Takehiko Fujiwara; Masatoshi Itoh; Hiroshi Fukuda; Keiichirou Yamaguchi; Kazuo Kubota; Jun Hatazawa; Masao Tada; Tatsuo Ido; Shouichi Watanuki

doi:10.1016/0360-3016(90)90026-G

Clinical assessment of therapeutic effects on cancer using ¹⁸F-2-fluoro-2-deoxy-d-glucose and positron emission tomography: Preliminary study of lung cancer

Yoshinao Abe, Taiju Matsuzawa, Takehiko Fujiwara, Masatoshi Itoh, Hiroshi Fukuda, Keiichirou Yamaguchi, Kazuo Kubota, Jun Hatazawa, Masao Tada, Tatsuo Ido, Shouichi Watanuki

Cyclotron and Radioisotope Center (CYRIC)

Research output: Contribution to journal › Article › peer-review

61 Citations (Scopus)

Abstract

Using positron emission tomography, we studied the tumor uptake of ¹⁸F-2-fluoro-2-deoxy-D-glucose (¹⁸FDG) in five lung cancer patients before and after anti-cancer therapy (radiotherapy and/or chemotherapy). The tumor uptake of ¹⁸FDG was classified as positive and negative; the former, by increasing the uptake of ¹⁸FDG with time, and the latter, by decreasing or the constant uptake of ¹⁸FDG. Before therapy, all cases tested positive. After therapy, three cases were negative and two cases remained positive. All negative cases corresponded to complete responses, and positive cases showed partial responses accompanying tumor regrowth 2 or 3 months after the second ¹⁸FDG study. Our findings in the ¹⁸FDG study correlate with the clinical results. ¹⁸FDG is a promising method for assessing therapeutic effects on cancer clinically.

Original language	English
Pages (from-to)	1005-1010
Number of pages	6
Journal	International Journal of Radiation Oncology, Biology, Physics
Volume	19
Issue number	4
DOIs	https://doi.org/10.1016/0360-3016(90)90026-G
Publication status	Published - 1990 Oct

Keywords

F-2-fluoro-2-deoxy-D-glucose
Lung cancer
Positron emission tomography
Therapeutic effects of cancer

ASJC Scopus subject areas

Radiation
Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/0360-3016(90)90026-G

Cite this

Abe, Y., Matsuzawa, T., Fujiwara, T., Itoh, M., Fukuda, H., Yamaguchi, K., Kubota, K., Hatazawa, J., Tada, M., Ido, T., & Watanuki, S. (1990). Clinical assessment of therapeutic effects on cancer using ¹⁸F-2-fluoro-2-deoxy-d-glucose and positron emission tomography: Preliminary study of lung cancer. International Journal of Radiation Oncology, Biology, Physics, 19(4), 1005-1010. https://doi.org/10.1016/0360-3016(90)90026-G

Clinical assessment of therapeutic effects on cancer using ¹⁸F-2-fluoro-2-deoxy-d-glucose and positron emission tomography: Preliminary study of lung cancer. / Abe, Yoshinao; Matsuzawa, Taiju; Fujiwara, Takehiko et al.
In: International Journal of Radiation Oncology, Biology, Physics, Vol. 19, No. 4, 10.1990, p. 1005-1010.

Research output: Contribution to journal › Article › peer-review

Abe, Y, Matsuzawa, T, Fujiwara, T, Itoh, M, Fukuda, H, Yamaguchi, K, Kubota, K, Hatazawa, J, Tada, M, Ido, T & Watanuki, S 1990, 'Clinical assessment of therapeutic effects on cancer using ¹⁸F-2-fluoro-2-deoxy-d-glucose and positron emission tomography: Preliminary study of lung cancer', International Journal of Radiation Oncology, Biology, Physics, vol. 19, no. 4, pp. 1005-1010. https://doi.org/10.1016/0360-3016(90)90026-G

@article{5b8d2df8713448e2a47dcd6f3fd923bc,

title = "Clinical assessment of therapeutic effects on cancer using 18F-2-fluoro-2-deoxy-d-glucose and positron emission tomography: Preliminary study of lung cancer",

abstract = "Using positron emission tomography, we studied the tumor uptake of 18F-2-fluoro-2-deoxy-D-glucose (18FDG) in five lung cancer patients before and after anti-cancer therapy (radiotherapy and/or chemotherapy). The tumor uptake of 18FDG was classified as positive and negative; the former, by increasing the uptake of 18FDG with time, and the latter, by decreasing or the constant uptake of 18FDG. Before therapy, all cases tested positive. After therapy, three cases were negative and two cases remained positive. All negative cases corresponded to complete responses, and positive cases showed partial responses accompanying tumor regrowth 2 or 3 months after the second 18FDG study. Our findings in the 18FDG study correlate with the clinical results. 18FDG is a promising method for assessing therapeutic effects on cancer clinically.",

keywords = "F-2-fluoro-2-deoxy-D-glucose, Lung cancer, Positron emission tomography, Therapeutic effects of cancer",

author = "Yoshinao Abe and Taiju Matsuzawa and Takehiko Fujiwara and Masatoshi Itoh and Hiroshi Fukuda and Keiichirou Yamaguchi and Kazuo Kubota and Jun Hatazawa and Masao Tada and Tatsuo Ido and Shouichi Watanuki",

year = "1990",

month = oct,

doi = "10.1016/0360-3016(90)90026-G",

language = "English",

volume = "19",

pages = "1005--1010",

journal = "International Journal of Radiation Oncology Biology Physics",

issn = "0360-3016",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Clinical assessment of therapeutic effects on cancer using 18F-2-fluoro-2-deoxy-d-glucose and positron emission tomography

T2 - Preliminary study of lung cancer

AU - Abe, Yoshinao

AU - Matsuzawa, Taiju

AU - Fujiwara, Takehiko

AU - Itoh, Masatoshi

AU - Fukuda, Hiroshi

AU - Yamaguchi, Keiichirou

AU - Kubota, Kazuo

AU - Hatazawa, Jun

AU - Tada, Masao

AU - Ido, Tatsuo

AU - Watanuki, Shouichi

PY - 1990/10

Y1 - 1990/10

N2 - Using positron emission tomography, we studied the tumor uptake of 18F-2-fluoro-2-deoxy-D-glucose (18FDG) in five lung cancer patients before and after anti-cancer therapy (radiotherapy and/or chemotherapy). The tumor uptake of 18FDG was classified as positive and negative; the former, by increasing the uptake of 18FDG with time, and the latter, by decreasing or the constant uptake of 18FDG. Before therapy, all cases tested positive. After therapy, three cases were negative and two cases remained positive. All negative cases corresponded to complete responses, and positive cases showed partial responses accompanying tumor regrowth 2 or 3 months after the second 18FDG study. Our findings in the 18FDG study correlate with the clinical results. 18FDG is a promising method for assessing therapeutic effects on cancer clinically.

AB - Using positron emission tomography, we studied the tumor uptake of 18F-2-fluoro-2-deoxy-D-glucose (18FDG) in five lung cancer patients before and after anti-cancer therapy (radiotherapy and/or chemotherapy). The tumor uptake of 18FDG was classified as positive and negative; the former, by increasing the uptake of 18FDG with time, and the latter, by decreasing or the constant uptake of 18FDG. Before therapy, all cases tested positive. After therapy, three cases were negative and two cases remained positive. All negative cases corresponded to complete responses, and positive cases showed partial responses accompanying tumor regrowth 2 or 3 months after the second 18FDG study. Our findings in the 18FDG study correlate with the clinical results. 18FDG is a promising method for assessing therapeutic effects on cancer clinically.

KW - F-2-fluoro-2-deoxy-D-glucose

KW - Lung cancer

KW - Positron emission tomography

KW - Therapeutic effects of cancer

UR - http://www.scopus.com/inward/record.url?scp=0025049165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025049165&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(90)90026-G

DO - 10.1016/0360-3016(90)90026-G

M3 - Article

C2 - 2170302

AN - SCOPUS:0025049165

SN - 0360-3016

VL - 19

SP - 1005

EP - 1010

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

IS - 4

ER -